Toxic Epidermal Necrolysis: Clinical Trials

5 trials for Toxic Epidermal Necrolysis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 withdrawn, 1 not yet recruiting, 1 recruiting, 1 terminated. 5 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Withdrawn 2, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 14Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1

Follow Toxic Epidermal Necrolysis: new trials by email Literature Review of Toxic Epidermal Necrolysis trials Research Report on Toxic Epidermal Necrolysis

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy
Phase 1 / Phase 2Not yet recruitingHospices Civils de Lyon92025-10-292025-08-07
LYell SYndrome MEsenchymal Stromal Cells Treatment
Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome
Phase 1 / Phase 2RecruitingAssistance Publique - Hôpitaux de Paris152024-04-152025-08-01
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis
Phase 1 / Phase 2WithdrawnUniversity of California, Davis2016-11-012019-08-09
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Phase 1 / Phase 2TerminatedBrett King12010-10-012016-11-30
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
Remicaide (infliximab) - Toxic Epidermal Necrolysis
Phase 2WithdrawnLoyola University2006-07-012013-04-26

Narrower conditions

Stevens-Johnson Syndrome (5)

Broader conditions

Chemically-Induced Disorders (5)  ·  Dermatitis (5)  ·  Drug Eruptions (5)  ·  Drug Hypersensitivity (5)  ·  Drug-Related Side Effects and Adverse Reactions (5)  ·  Erythema (5)  ·  Erythema Multiforme (5)  ·  Hypersensitivity (5)  ·  Hypersensitivity, Delayed (5)  ·  Immune System Diseases (5)  ·  Mouth Diseases (5)  ·  Skin Diseases (5)  ·  Skin Diseases, Vesiculobullous (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Stomatitis (5)

Interventions

Clobetasol (1)  ·  Fibroblast Growth Factor 7 (1)  ·  Infliximab (1)  ·  Ointments (1)  ·  daratumumab (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (1)  ·  Brett King (1)  ·  Hospices Civils de Lyon (1)  ·  Loyola University (1)  ·  University of California, Davis (1)

Countries

France (2)  ·  United States (2)

Top investigators

Emanual Maverakis, MD (1)  ·  Richard Gamelli, MD (1)  ·  Saskia Oro, PhD (1)

Results publications

PMID 26297574, PMID 28476287